Bristol Myers Squibb, US1101221083

Bristol Myers Squibb stock: cancer deal, EUR 54.41, down 0.64%

Published on 11/19/2026 at 08:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb will sponsor a Phase 1/2 pancreatic cancer study with Erasca. On Xetra, the stock closed at EUR 54.76 on Wednesday, November 18, 2026.

Key points for investors

  • Bristol Myers Squibb will sponsor a Phase 1/2 pancreatic cancer trial with Erasca.
  • The study will combine ERAS-0015 with BMS's investigational PRMT5 inhibitor navlimetostat.
  • The companies will retain development and commercial rights to their respective compounds.
Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb stock traded at EUR 54.41 on Lang & Schwarz at 08:24 CET on Thursday, November 19, 2026, 0.64 percent below the Xetra close of EUR 54.76 on Wednesday, November 18, 2026.

The move comes as the biopharmaceutical company advances a new oncology collaboration. In a November 17 announcement, Erasca said the companies had entered a clinical trial collaboration and supply agreement.

New pancreatic cancer collaboration

The planned Phase 1/2 study will evaluate Erasca's investigational pan-RAS molecular glue ERAS-0015 with navlimetostat, also known as BMS-986504, in patients with MTAP-deleted pancreatic ductal adenocarcinoma. Bristol Myers Squibb will sponsor the trial, while Erasca will supply ERAS-0015.

Each company will retain development and commercial rights to its own compound, and the agreement is mutually non-exclusive. Erasca said the combination is intended to address tumors in which MTAP deletion and RAS mutations frequently occur together. The clinical study is expected to test the scientific rationale for simultaneous RAS and PRMT5 inhibition.

ERAS-0015 is also being evaluated in Erasca's AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors. The collaboration adds a pancreatic cancer combination program to Bristol Myers Squibb's investigational oncology pipeline, but the combination's safety and efficacy remain subject to clinical testing.

For the broader market, investors can follow the S&P 500 alongside the stock.

More news and analyses on Bristol Myers Squibb stock

Disclaimer...
en | US1101221083 | BRISTOL MYERS SQUIBB | boerse | 70534451 | bgmi